Cancers are the leading cause of death in Switzerland among people under 85 years of age. New drug treatments, not yet available on the market, are developed each year and represent a huge hope for patients. The Onco-Hematology Clinical Research Unit Dr. Henri Dubois-Ferrière Foundation Dinu Lipatti provides access to new molecules for adult patients with onco-hematological conditions in clinical trials. Created through a partnership between the HUG, the UNIGE Faculty of Medicine and the Dr. Henri Dubois-Ferriere Dinu Lipatti Foundation, the DFDL Research Unit provides patients with access to promising anti-cancer therapies of various types: antibodies, selective inhibitors, immunomodulators, cell therapy, therapeutic vaccination, etc. Recognized by the Swiss Group for Experimental Research against Cancer as one of the few centers of excellence in Switzerland for the conduct of Phase I studies, known as "first in human", the DFDL Research Unit is also certified by the Novartis firm as one of its few centers authorized to perform early stage studies.

Nephrology